ClinicalTrials.gg

Program

lunsekimig

Also written as “Lunsekimig” and “SAR443765”.

In Sanofi's pipeline, IL13xTSLP Nanobody VHH. Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Nasal Polyps · Dermatitis, Atopic, led by Sanofi.

Furthest: phase 3, since Sep 17, 202510 company-led studies, 6 open or runningNext primary completion: Jun 21, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi106 open or runningphase 3since Sep 17, 2025May 4, 2022Jun 21, 2027phase 2 · NCT06676319
  • Named in Sanofi’s own pipeline as lunsekimig, phase 3, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 4, 2022First study: phase 1 study in AsthmaFirst studyNCT05366764 · 36 enrolled · Germany, United Kingdom
  2. Oct 20, 2023Phase 2 study in AsthmaNCT06102005 · 685 enrolled · United States, Argentina, Brazil and more
  3. Jun 6, 2024Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT06454240 · 79 enrolled · United States, Argentina, Belgium and more
  4. Sep 20, 2024Phase 2 study in AsthmaNCT06609239 · 900 planned · United States, Argentina, Brazil and more
  5. Nov 4, 2024Phase 2 study in AsthmaNCT06676319 · 556 enrolled · United States, Argentina, Belgium and more
  6. Jan 17, 2025Phase 2 study in Dermatitis, AtopicNCT06790121 · 150 enrolled · United States, Czechia, Japan and more
  7. Apr 4, 2025Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT06914908 · 71 enrolled · United States, Argentina, Belgium and more
  8. Sep 17, 20252 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNCT07190222, NCT07190209
  9. Aug 25, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07793409 · 1,508 planned · United States, Canada, United Kingdom

Ahead

  1. Jun 21, 2027Primary completion: phase 2 study in AsthmaNCT06676319
  2. Feb 22, 2029Primary completion: phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT06914908
  3. Nov 27, 2029Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07190222
  4. Nov 27, 2029Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07190209

TargetBeta

“IL13xTSLP Nanobody VHH”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
tilrekimigPfizerphase 311

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07793409Pulmonary Disease, Chronic Obstructive · United States, Canada, United Kingdom3By invitationJul 23, 20311,508
NCT07190222Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3RecruitingNov 27, 2029942
NCT07190209Pulmonary Disease, Chronic Obstructive · United States, Argentina, Belgium and more3RecruitingNov 27, 2029942
NCT06914908Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Belgium and more2Active, not recruitingFeb 22, 202971
NCT06790121Dermatitis, Atopic · United States, Czechia, Japan and more2CompletedFeb 12, 2026150
NCT06676319Asthma · United States, Argentina, Belgium and more2Active, not recruitingJun 21, 2027556
NCT06609239Asthma · United States, Argentina, Brazil and more2By invitationJan 20, 2031900
NCT06454240Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Belgium and more2CompletedJan 29, 202679
NCT06102005Asthma · United States, Argentina, Brazil and more2CompletedFeb 23, 2026685
NCT05366764Asthma · Germany, United Kingdom1CompletedFeb 24, 202336

How it is read

Names in the registry

  • “Lunsekimig”, 8 entries
  • “lunsekimig”, 1 entry
  • “SAR443765”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.